Lazard Asset Management
TPTX

Lazard Asset Management’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Lazard Asset Management’s Portfolio TPTX Stock Details TPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-792
Closed -$61K – 2340
2021
Q2 		$61K Buy
+792
New +$58.5K ﹤0.01% 1517
2021
Q1 		– Sell
-572
Closed -$69K – 2090
2020
Q4 		$69K Buy
+572
New +$62.7K ﹤0.01% 1286

Other funds holding TPTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Lazard Asset Management's TPTX Position: Q3 2021 in Review

Lazard Asset Management sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2021, closing a stake of 792 shares — an estimated $61K sold.

Lazard Asset Management first reported a position in TPTX in Q4 2020 and held it in 2 quarters. The position peaked at $69K in Q4 2020. 190 funds tracked by Wall St. Rank hold TPTX as of Q3 2021.

  • Lazard Asset Management reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Lazard Asset Management sold 792 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2021, an estimated $61K.
  • Lazard Asset Management first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q4 2020 and held it in 2 quarters.
  • Lazard Asset Management's Turning Point Therapeutics, Inc. Common Stock position peaked at $69K in Q4 2020.
  • 190 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2021.

Based on Lazard Asset Management's 13F filing for Q3 2021, filed 15 Nov 2021.